AirSculpt Technologies, Inc. (NASDAQ:AIRS) CEO Dennis Dean Sells 24,510 Shares

AirSculpt Technologies, Inc. (NASDAQ:AIRS) CEO Dennis Dean sold 24,510 shares of AirSculpt Technologies stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $6.54, for a total transaction of $160,295.40. Following the completion of the sale, the chief executive officer now directly owns 582,052 shares in the company, valued at $3,806,620.08. This trade represents a 4.04 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Dennis Dean also recently made the following trade(s):

• On Wednesday, November 13th, Dennis Dean sold 7,719 shares of AirSculpt Technologies stock. The stock was sold at an average price of $7.53, for a total value of $58,124.07.

AirSculpt Technologies Stock Performance

Shares of AIRS stock opened at $6.51 on Friday. AirSculpt Technologies, Inc. has a 12 month low of $2.92 and a 12 month high of $9.20. The stock has a market capitalization of $376.81 million, a P/E ratio of -46.50 and a beta of 1.57. The company has a current ratio of 0.51, a quick ratio of 0.86 and a debt-to-equity ratio of 0.80. The firm’s 50 day moving average is $5.55 and its 200 day moving average is $4.75.

AirSculpt Technologies (NASDAQ:AIRS) last posted its earnings results on Friday, November 8th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.05). AirSculpt Technologies had a positive return on equity of 2.22% and a negative net margin of 4.13%. The company had revenue of $42.55 million for the quarter, compared to analysts’ expectations of $42.49 million. During the same quarter in the prior year, the company earned ($0.01) EPS. On average, sell-side analysts anticipate that AirSculpt Technologies, Inc. will post 0.15 earnings per share for the current year.

Analyst Ratings Changes

Separately, BTIG Research started coverage on AirSculpt Technologies in a research report on Thursday, October 17th. They set a “neutral” rating on the stock. Five investment analysts have rated the stock with a hold rating, According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $5.50.

Institutional Investors Weigh In On AirSculpt Technologies

Hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in shares of AirSculpt Technologies by 1.0% in the first quarter. Vanguard Group Inc. now owns 576,038 shares of the company’s stock valued at $3,537,000 after acquiring an additional 5,606 shares during the period. Barclays PLC lifted its stake in AirSculpt Technologies by 227.0% in the 3rd quarter. Barclays PLC now owns 19,100 shares of the company’s stock worth $97,000 after purchasing an additional 13,259 shares in the last quarter. Geode Capital Management LLC boosted its holdings in AirSculpt Technologies by 6.4% in the 3rd quarter. Geode Capital Management LLC now owns 355,540 shares of the company’s stock valued at $1,803,000 after purchasing an additional 21,339 shares during the period. FourWorld Capital Management LLC purchased a new position in shares of AirSculpt Technologies during the 1st quarter valued at $557,000. Finally, SW Investment Management LLC grew its position in shares of AirSculpt Technologies by 5.0% during the 2nd quarter. SW Investment Management LLC now owns 4,500,000 shares of the company’s stock valued at $18,000,000 after purchasing an additional 213,677 shares in the last quarter. 91.54% of the stock is currently owned by institutional investors.

About AirSculpt Technologies

AirSculpt Technologies, Inc, together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States. The company offers AirSculpt, a next-generation body contouring procedure that removes unwanted fat and tightens skin in a minimally invasive procedure.